MEDIAN Technologies signs a €384K contract with a San Francisco-area Biotech Company

Sophia Antipolis, France

MEDIAN Technologies will provide imaging services for a phase II study on lung cancer.

MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced that it has signed a contract with a San Francisco-area based biotech company.  The contract amount is €384,000 (eq. $ 524,500).

MEDIAN Technologies will provide imaging services to support a phase II clinical trial for advanced non-small cell lung cancer. Within the framework of the study, imaging data will be acquired from 90 clinical sites, based in 12 European countries, in the US, and in Canada. Anticipated total enrollment is 440 patients with a “first patient in” forecasted May, 2014. MEDIAN will supply a set of services including clinical site qualification and training, as well as image and data collection, quality control, and storage.

“We are pleased to start 2014 supporting this important trial for a new, hypoxia-targeted therapy,” said Ciaran Cooper, Head of Business Development, Clinical Trials Imaging, North America.Adding this new biotech client demonstrates that our imaging services bring value not only to major pharmaceutical companies, but to top biotechnology companies as well.”

Download Contract_20140109.pdf